Bedrijfsoverzicht
Kewaunee Scientific Corporation is a specialized manufacturer dedicated to the design, production, and installation of laboratory, healthcare, and technical furniture along with associated infrastructure products for diverse sectors. Operating within the Consumer Cyclical sector and specifically the Furnishings, Fixtures & Appliances industry, the company supplies essential equipment that supports scientific research and medical facilities. The enterprise employs a workforce of 1239 individuals and holds a total market capitalization of $100.11M, reflecting its status as a mid-cap entity within its niche. With an annual revenue of $287.75M, the company demonstrates a substantial operational footprint that allows it to compete effectively while maintaining a focused product portfolio including steel and wood casework, fume hoods, and adaptable modular systems.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $287.75M, generating a net income of $11.08M and an EBITDA of $26.02M, which highlights a significant disparity between top-line sales and bottom-line profitability that underscores a high cost structure or substantial operating expenses. This gap reveals that for every dollar of revenue generated, a considerable portion is consumed by costs before reaching the net income figure, leaving a relatively thin profit buffer. The firm produced $15.47M in free cash flow, indicating a positive ability to generate cash after capital expenditures, which provides the financial flexibility necessary for debt servicing or potential strategic investments. Profitability efficiency is further illustrated by a gross margin of 28.9%, an operating margin of 3.7%, and a profit margin of 3.9%, all of which suggest that while the company maintains pricing power, its operational leverage is constrained by high overhead or competitive pricing pressures. On the balance sheet, the company holds $8.15M in cash against $59.34M in total debt, resulting in a debt-to-equity ratio of 81.82, which indicates a leveraged position where debt obligations significantly exceed equity holdings. Liquidity is supported by a current ratio of 2.12, signaling that the company possesses more than twice the current assets needed to cover its short-term liabilities, thereby ensuring a comfortable margin of safety for immediate obligations. Management effectiveness is evidenced by a return on equity of 17.4% and a return on assets of 6.8%, metrics that demonstrate the company generates substantial returns on shareholder capital relative to its asset base, despite the noted earnings pressure.
Waarderingsbeoordeling
Valuation metrics for Kewaunee Scientific Corporation show a trailing P/E ratio of 9.39 compared to a forward P/E of 16.17, implying that the market expects earnings to decline or stabilize before growing, as the forward multiple is significantly higher than the historical average. The price-to-book ratio stands at 1.42, indicating that the market values the company at a modest premium over its book value, suggesting that intangible assets or growth potential are priced into the stock. Alternative valuation perspectives include a price-to-sales ratio of 0.35 and an EV/EBITDA of 5.89, which collectively suggest the stock is trading at a discount relative to revenue generation and earnings before interest, taxes, depreciation, and amortization when adjusted for enterprise value. Price action over the last year has seen the stock fluctuate between a 52-week low of $30.33 and a 52-week high of $60.89, with the current trading price situated near the lower end of this historical range based on the available data points. The beta value of 0.67 indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting it may act as a defensive holding during periods of heightened market uncertainty.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of 3.3% year-over-year contrasted with an earnings growth rate of -48.9% year-over-year, revealing that earnings are contracting much faster than revenue, which implies deteriorating profitability or margin compression rather than top-line expansion issues. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that the firm retains all its earnings to fund operations, pay down debt, or reinvest in the business rather than distributing income to shareholders. This strategy of non-dividend payment aligns with the company's current financial profile where free cash flow and earnings are being prioritized for internal stability rather than shareholder payouts. Overall, the growth and income profile presents a scenario of stable but slow revenue expansion coupled with significant earnings contraction and no current income distribution to investors.